1. Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer
   Elena Bolzacchini et al, 2017, Journal of Thoracic Oncology CrossRef
2. Efficacy of osimertinib in a patient with non‑small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status
   Yoichi Nishii et al, 2017, Molecular and Clinical Oncology CrossRef
3. Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
   Aladdin Kanbour et al, 2022, OncoTargets and Therapy CrossRef
4. Osimertinib
   Umberto Malapelle et al, 2018, Small Molecules in Oncology CrossRef
5. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report
   Junjun Li et al, 2018, Molecular and Clinical Oncology CrossRef
6. Efficacy of osimertinib against EGFRvIII+ glioblastoma
   Gustavo Chagoya et al, 2020, Oncotarget CrossRef
7. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer
   Manmeet S. Ahluwalia et al, 2018, The Oncologist CrossRef
8. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
   James C.H. Yang et al, 2020, Journal of Clinical Oncology CrossRef
9. Systematic analysis of the potential off-target activities of osimertinib by computational target fishing
   Shao-jun Chen et al, 2022, Anti-Cancer Drugs CrossRef